Huma acquired AstraZeneca’s digital health platform, and AstraZeneca became a shareholder of Huma in a partnership to accelerate digital patient care.
Huma announced on March 23, 2022 that it has partnered with AstraZeneca to scale and accelerate digital health innovation. The companies will launch Software as a Medical Device (SaMD) companion apps targeted to multiple therapeutic areas and partner to help accelerate the adoption of decentralized clinical trials.
Huma already has technology that powers digital-first care, serving more than 1.8 million active patient users across more than 3,000 hospitals and clinics. The technologies are designed to provide more efficient care delivery by connecting to clinical workflows.
AstraZeneca has invested in the development of its AMAZE digital health platform to improve patient care and management. The collaboration with Huma will combine with the strong foundation of AMAZE to accelerate digital care across all therapeutic areas and launch SaMDs.
“This collaboration marks an important moment as it is a first for AstraZeneca in the field of digital health as well as in the chronic disease and SaMD industry in support of different treatments,” said Karan Arora. , AstraZeneca’s Chief Digital Officer, in a “Together with Huma, we are accelerating AstraZeneca’s ambition to achieve earlier diagnosis and treatment for patients with chronic conditions so they can lead better and longer lives. fulfilling.”